InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,598.80
(
1.03%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.32
(
-0.19%
)
Bitcoin
63,419.35
(
0.39%
)
Post# of 3329
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

FredKerx

Send PM Follow Ignore
Followers 1
Posts 127
Boards Moderated 0
Alias Born 02/15/2018

FredKerx

Re: None

Saturday, 03/31/2018 2:42:27 PM

Saturday, March 31, 2018 2:42:27 PM

Post# of 3329
Yes Keryx executive management...

IDA in CKD is different, it’s complicated, and you have a blockbuster drug ($1 billion Renvela on steroids) with pristine clinical results for years. You also have 2 FDA approvals, the last one granted 5 months ago which exponentially increases market potential. You also have broad label EU approval since 21/2 years ago with New Active Substance designation which provides 10 years of data and marketing exclusivity in Europe.You also have 27,300 sq. ft. multi-million renovated offices with an organization structure a la Big Pharma footprint of 210 head count. You also have hefty compensation and benefit package with free stock awards/RSUs. You also just spent $100 million in SG&A in 2017.

So why is KERX’s stock price at $4 ??? ??

https://t.co/IhhMyMDeLI

$4 ??? ??

https://mobile.twitter.com/keryxbio/status/978273474593554434

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up